Modern surgical strategies and mechanical circulatory support yield excellent survival even among the sickest patients with acute pulmonary embolism, the AHA notes in a new scientific statement.
As compared with low-molecular-weight heparin, direct oral anticoagulants (DOACs) were more clinically effective and more cost-effective for treating cancer-associated thrombosis.
Non-White patients with pulmonary embolism (PE) were less likely to get advanced therapies, and Hispanics and Asians/Pacific Islanders, had higher death rates than Whites, new data show.